Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Argatra; Denmark: Novastan; Germany: Argatra; Greece: Argatroban; Italy: Novastan; Netherlands: Arganova; Sweden: Novastan.

North America

Canada: Argatroban; USA: Argatroban.


Japan: Argaron, Argatroban, Gartban, Novastan, Slonnon, Slovastan.

Drug combinations


Argatroban: C~23~H~36~N~6~O~5~S H~2~O. Mw: 526.65. (1) 2-Piperidinecarboxylic acid, 1-[5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-, monohydrate; (2)(2R,4R)-4-Methyl-1-[N^2^-[(1,2,3,4-tetrahydro-3-methyl-8-quinolyl)sulfonyl]-L-arginyl]pipecolic acid, monohydrate. CAS-141396-28-3; CAS-74863-84-6 (anhydrous)(1997).

Pharmacologic Category

Antithrombotic Agents; Anticoagulants; Direct Thrombin Inhibitors. (ATC-Code: B01AE03).

Mechanism of action

Reversibly binds to the active thrombin site of free and clot-associated thrombin. Inhibits fibrin formation, activation of coagulation factors V, VIII, and XIII, protein C, and platelet aggregation.

Therapeutic use

Prophylaxis or treatment of thrombosis with heparin-induced thrombocytopenia. Adjunct to percutaneous coronary intervention in patients who have or are at risk of thrombosis associated with heparin-induced thrombocytopenia.

Pregnancy and lactiation implications

Should be used during pregnancy only if clearly needed. Use not recommended during lactation.

Unlabeled use


Hypersensitivity to argatroban or any component of the formulation. Overt major bleeding.

Warnings and precautions

Bleeding is common. Use with caution in hepatic impairment or in critically-ill patients. Parenteral anticoagulants should be discontinued prior to initiating therapy. Concomitant use with warfarin will cause increased prolongation of the PT and INR.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart